What are the starting doses for estrogen and progesterone therapy in postmenopausal women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Starting Doses for Estrogen and Progesterone in Postmenopausal Women

For postmenopausal women requiring hormone therapy, the recommended starting doses are oral conjugated equine estrogen 0.625 mg/day with medroxyprogesterone acetate 2.5 mg/day for women with an intact uterus, or estrogen alone for women who have had a hysterectomy. 1

Estrogen Dosing Options

Oral Estrogen

  • Conjugated equine estrogen: 0.625 mg/day 1, 2

Transdermal Estrogen

  • Transdermal estradiol patch: 0.025-0.0375 mg/day 2
    • Preferred for women with hypertension, liver disease, or elevated thrombosis risk due to lower thromboembolism risk compared to oral formulations

Progesterone Dosing Options

For Women with Intact Uterus

Progesterone must always be added to estrogen therapy in women with an intact uterus to prevent endometrial hyperplasia and cancer.

Continuous Combined Regimen

  • Medroxyprogesterone acetate: 2.5 mg/day (daily) 1, 2
    • This dose has been shown to effectively prevent endometrial hyperplasia 3

Cyclic Regimen

  • Medroxyprogesterone acetate: 5-10 mg/day for 12-14 days per 28-day cycle 2
  • Micronized progesterone: 200 mg/day for 12-14 days per 28-day cycle 2, 4

Important Clinical Considerations

Risk Assessment

Before initiating hormone therapy, it's crucial to assess:

  • Risk factors for cardiovascular disease, stroke, and venous thromboembolism
  • Personal or family history of breast cancer
  • Liver function
  • History of endometrial cancer or hyperplasia

Contraindications

Hormone therapy is contraindicated in women with:

  • Active liver disease
  • History of breast cancer
  • History of coronary heart disease
  • Previous venous thromboembolism or stroke 2

Risk-Benefit Profile

The USPSTF found that hormone therapy is associated with:

  • Benefits: Reduced risk of fractures
  • Risks: Increased risk of stroke, dementia, gallbladder disease, urinary incontinence, breast cancer, and venous thromboembolism 1

Monitoring

  • Regular follow-up at 3-6 month intervals initially
  • Annual assessment including blood pressure, weight, lipid profile, and cancer screening 2
  • Evaluate for symptoms of estrogen excess (breast tenderness, fluid retention, headaches, nausea, mood changes)

Special Considerations

Women with Hysterectomy

  • Estrogen alone (without progesterone) is appropriate 1
  • Oral conjugated equine estrogen: 0.625 mg/day

Premature Ovarian Insufficiency

  • Higher doses may be required
  • Continue therapy until at least the average age of natural menopause (51 years) 2

Vasomotor Symptoms

  • If hormone therapy is primarily for vasomotor symptoms (hot flashes), use the lowest effective dose for the shortest duration possible
  • Non-hormonal alternatives include low-dose paroxetine, venlafaxine, and gabapentin 2

Remember that these recommendations are for starting doses, and adjustments may be needed based on symptom control and side effects. The USPSTF does not recommend hormone therapy for the primary prevention of chronic conditions, but rather for symptom management in appropriate candidates 1.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.